Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
January 2018
in “
Figshare
”
TLDR Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
The study involved 80 patients with severe alopecia areata (AA) who were treated with either oral ruxolitinib or tofacitinib citrate over 6 months, followed by a 3-month follow-up. Patients were assessed monthly using the Severity of Alopecia Tool (SALT) scale to measure hair regrowth. Results showed varying degrees of improvement, categorized from low grade (0-24% improvement) to complete grade responders (100% improvement). The study concluded that both treatments were effective in promoting hair regrowth in patients with severe AA, with statistical significance set at p < 0.05.